57060-86-3Relevant articles and documents
New four-component Ugi-type reaction. Synthesis of 3-methyl-1-oxo-1,3,4,6, 11,11a-hexahydro-2H-pyrazino[1,2-b]isoquinoline-3-carboxamides
Ilyn, Alexey P.,Trifilenkov, Andrey S.,Kovrigin, Denis I.,Yudin, Michail V.,Ivachtchenko, Alexandre V.
, p. 107 - 110 (2006)
A small-sized library of novel 3,4,11,11a-tetrahydro-2H-pyrazino[1,2-b] isoquinolin-1(6H)-ones is synthesized. Key synthetic step is based on a new variant of Ugi four component reaction using bifunctional keto acids, amine and isocyanide as starting mate
NATURAL KILLER CELLS
-
Page/Page column 91-92; 98, (2020/01/24)
This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of IMK cells by increasing the expression of specific transcription factors associated with NK cell production.
Gene delivery system
-
Paragraph 0088; 0089, (2017/10/27)
The invention discloses a preparation method of a gene nano-liposome carrier Isoquinoline-3-acyl-RGDV(IRV) and an IRV/STAT3-siRNA gene delivery system. The IRV/STAT3-siRNA gene delivery system is composed of liposome carriers IRV and STAT3-siRNA, protamine and calf thymus DNA in a proportion, and has slow release and targeting effects. The cell transfection efficiency, the in-vitro anti-tumor activity, and the gene silencing efficiency and a cell action mechanism on the mRNA level and the protein level of a compound are evaluated with the lung cancer A549 cell strain as a model, and the result shows the IRV/STAT3-siRNA gene delivery system has more excellent anti-tumor activity and gene silencing efficiency compared with control groups. According to the system, the anti-tumor activity of the IRV/STAT3-siRNA gene delivery system is evaluated with an S180 ascites tumor mouse as a model, and the result shows that a 100% IRV/STAT3-siRNA group has an anti-tumor effect.